At What Price? A Cost-Effectiveness Analysis Comparing Trial of Labour after Previous Caesarean versus Elective Repeat Caesarean Delivery by Fawsitt, C.G. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/118021
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
At What Price? A Cost-Effectiveness Analysis Comparing
Trial of Labour after Previous Caesarean versus Elective
Repeat Caesarean Delivery
Christopher G. Fawsitt1,2*, Jane Bourke2, Richard A. Greene1, Claire M. Everard3, Aileen Murphy2,
Jennifer E. Lutomski1
1National Perinatal Epidemiology Centre, Cork, Ireland, 2 School of Economics, University College Cork, Cork, Ireland, 3Cork University Maternity Hospital, Cork, Ireland
Abstract
Background: Elective repeat caesarean delivery (ERCD) rates have been increasing worldwide, thus prompting obstetric
discourse on the risks and benefits for the mother and infant. Yet, these increasing rates also have major economic
implications for the health care system. Given the dearth of information on the cost-effectiveness related to mode of
delivery, the aim of this paper was to perform an economic evaluation on the costs and short-term maternal health
consequences associated with a trial of labour after one previous caesarean delivery compared with ERCD for low risk
women in Ireland.
Methods: Using a decision analytic model, a cost-effectiveness analysis (CEA) was performed where the measure of health
gain was quality-adjusted life years (QALYs) over a six-week time horizon. A review of international literature was conducted
to derive representative estimates of adverse maternal health outcomes following a trial of labour after caesarean (TOLAC)
and ERCD. Delivery/procedure costs derived from primary data collection and combined both ‘‘bottom-up’’ and ‘‘top-down’’
costing estimations.
Results: Maternal morbidities emerged in twice as many cases in the TOLAC group than the ERCD group. However, a TOLAC
was found to be the most-effective method of delivery because it was substantially less expensive than ERCD (J1,835.06
versus J4,039.87 per women, respectively), and QALYs were modestly higher (0.84 versus 0.70). Our findings were
supported by probabilistic sensitivity analysis.
Conclusions: Clinicians need to be well informed of the benefits and risks of TOLAC among low risk women. Ideally,
clinician-patient discourse would address differences in length of hospital stay and postpartum recovery time. While it is
premature advocate a policy of TOLAC across maternity units, the results of the study prompt further analysis and repeat
iterations, encouraging future studies to synthesis previous research and new and relevant evidence under a single
comprehensive decision model.
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Introduction
Whether women should attempt a trial of labour after caesarean
(TOLAC), rather than undergo an elective repeat caesarean
delivery (ERCD) is an important clinical decision. While TOLAC
is a viable birth option for many low risk women and is associated
with numerous benefits relative to ERCD [1,2], attempted
TOLAC rates vary dramatically across local hospitals and
internationally [3–7]. ERCD may be favoured over a trial of
labour due to medico-legal fears [8,9], potential risks to the mother
and fetus [10–12], or maternal preference [13]. However, the
increased frequency of elective caesarean delivery carries many
important economic implications. The cost to the health system is
typically greater than the cost of vaginal deliveries, and the impact
on a woman’s health related quality of life following the surgical
intervention is considerably more profound [2,14].
Costing mode of delivery is challenging. Hospital charges are
often cited as indication of the cost of care; however, these
standard charges rarely reflect the actual cost of providing a service
[15]. The actual cost of providing a service is best estimated by
identifying, measuring, and valuing all resources used in the
production of the service [16], known as the ‘‘bottom-up’’
approach or micro-costing. Internationally, attempts have been
made to estimate the delivery costs associated with a vaginal and
caesarean delivery by determining direct medical costs [17]; direct
and indirect medical costs, and fixed and variable costs [18];
hospital charges [19,20]; cost-to-charge ratios [21]; and per diem
rates [22], with some studies including physician fees in their
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analysis [21,22]. However, due to this wide variety of costing
techniques, these studies have reached divergent conclusions
regarding estimated mode of delivery costs. Whereas estimates in
the UK have found that a caesarean delivery costs more than
double a vaginal delivery [23], two studies conducted in the US
have contradicted this finding [17,20]. For instance, Kazandjian
et al found that the average cost of a vaginal delivery in the US
may be higher than the average cost of a caesarean delivery when
certain maternal characteristics are accounted for, such as
maternal race and the presence of maternal co-morbidities [21].
This study contributes to and enhances existing costing estima-
tions. It applies a ‘‘bottom-up’’ approach in its evaluation of both
delivery procedures, accounting for medical supplies, pharmaceu-
ticals, and staff costs. The exhaustive costing technique provides
invaluable information on the total cost of care following
a TOLAC and ERCD expressed in Euros.
The obstetric course of women with a previous uterine scar
attracts major public policy concern as the clinical decision does
not just affect the woman and infant but also the health care
system and, moreover, society as a whole. Over the last 30 to 40
years, researchers have attempted to discern the appropriate mode
of delivery for women who are considered at low risk of obstetric
complications. However, most studies have found conflicting
evidence, with some studies suggesting that a TOLAC is associated
with greater maternal morbidities than an ERCD [24–26] while
other studies have demonstrated the opposite [2]. Few studies have
incorporated the economic implications of the clinical decision in
their analysis but with little appeal to public and clinical conviction
[21,22]. To determine the most suitable mode of delivery for low
risk women from a public policy perspective, research must
converge on a point where the level of uncertainty surrounding the
expected clinical outcome is minimised [27]. This involves
numerous evaluations, along with the amalgamation of previous
research, or synthesis of evidence. In health economics, this
approach is referred to as the iterative framework of economic
evaluation [28–30]. Because this study represents the first of its
kind in a European setting, it begins the iterative approach to
determining the appropriate mode of delivery for women with
a previous uterine scar. The results of this evaluation therefore
carry important implications for future research but cannot
represent true cost-effectiveness.
Economic evaluations are undertaken to inform decision
making, whether it is to determine the effectiveness of a new drug
or health technology or the cost-effectiveness of an existing
treatment. Cost-effectiveness analysis (CEA) is a particular type of
economic evaluation that compares the costs and effects of two or
more comparators [16]. The outcome measurement is expressed
in terms of an incremental cost-effectiveness ratio (ICER). Using
standard cost-effectiveness analysis methods, the aim of this study
was to examine the costs and short-term maternal outcomes
associated with a TOLAC and an ERCD for a hypothetical cohort
of low risk women. Low risk women were defined according to the
National Institute for Health and Clinical Excellence (NICE)
guidelines on intrapartum care [31]. The study assumed the
perspective of the health system in Ireland and considered a six
week time horizon. This allowed for variations in health-related
quality of life arising from maternal complications and each
delivery pathway, with average postpartum recovery time rarely
exceeding three weeks, while also allowing for one follow-up
consultation in the event of puerperal infection and its associated
impact on health-related quality of life.
Methods
To compare the costs and consequences of a TOLAC
compared with an ERCD, a decision analytic model was
employed. Decision modelling can be defined as the systematic
approach to decision-making under conditions of uncertainty [27].
In a decision analytic model, consequences are expressed as
probabilities, weighted against costs and outcomes to derive an
expected value for each alternative option. To represent the
model, thus capturing all possible consequences that could flow
from the decision to undergo a TOLAC or an ERCD, a decision-
tree model was used (Figure 1). In this model, a woman could have
a successful TOLAC or fail the trial, resulting in an emergency
caesarean delivery. A successful TOLAC encompassed both
unassisted and assisted vaginal deliveries – ventouse delivery was
modelled as an assisted vaginal delivery because it is more
commonly used in Ireland, accounting for 12.2% of all deliveries
in 2009 [32]. In either case, a woman could have a complication-
free delivery (‘Healthy’), suffer a maternal morbidity (‘Morbidity’), or
die (‘Death’); the same maternal outcomes arose following an
emergency caesarean section and ERCD. Using a Bayesian
technique, maternal complications were grouped into one health
state where the probability of an event was weighted according to
its proportional size to overall morbidities [27].
In order to complete a decision analytic model, data on
TOLAC success rates, potential adverse health events, and
delivery costs were required. Information on TOLAC success
rates was available from seven of the 20 maternity hospitals in
Ireland, representing 61.6% of all deliveries in the country in
2009. The data are assumed representative of the general obstetric
population as more than half of all births were captured by the
seven hospitals during this period. Of the group attempting
a TOLAC in 2009, two-thirds (66.6%) were successful. While the
rate of ventouse deliveries in the TOLAC group was unavailable
in individual hospital reports, nationally representative hospital
discharge data found that 12.2% of all deliveries were ventouse
deliveries during 2009 [32]. Since the rate may be higher in
women attempting a TOLAC, in the decision tree, a base case
estimate of 13% was assumed. Variation in the rate of assisted
deliveries was accounted for in the probabilistic sensitivity analysis.
A hypothetical cohort of 10,000 low risk women was used in the
decision analytic model to closely resemble morbidity patterns in
a small population.
Because there are no published Irish data on maternal
morbidity following a TOLAC or an ERCD, incidence rates
from a recent systematic review conducted in North America [2]
were used to derive the probability of an adverse event. The model
considered five major maternal complications which are com-
monly associated with a TOLAC and an ERCD and maternal
mortality. These morbidities included uterine rupture, hysterecto-
my, operative injury, blood transfusion, and postpartum endome-
tritis.
Cost data were compiled from primary data collection and
combined both ‘‘bottom-up’’ and ‘‘top-down’’ costing techniques.
As the study assumed the perspective of the health system, only
direct costs to the government were included. All unit costs were
expressed in Euro and valued at 2010 prices. Due to the short-
term nature of the economic evaluation, discounting was exempt
from the analysis as costs and outcomes accrued immediately
rather than in the future.
To identify all resources used during a TOLAC and an ERCD
along with other procedures, a resource use inventory was
developed and approved by a health economist (CGF), a clinical
manager midwife (CME) and a consultant obstetrician (RAG).
Cost-Effectiveness of a Trial of Labour
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The inventory identified all resources used during the various
procedures and alternative delivery pathways, including medical
supplies, pharmaceuticals, blood units, and time spent by each
healthcare professional with the woman in each instance. The
following procedures were micro-costed: epidural and spinal
injections, general anaesthetic, vaginal birth and ventouse birth,
caesarean section (elective and emergency), uterine rupture,
hysterectomy, operative injury, blood transfusion, endometritis,
and maternal mortality. The cost of an epidural was included in
the cost of a TOLAC because it is administered in approximately
60% of deliveries in Ireland (unpublished data; derived from the
Hospital In-Patient Enquiry (HIPE) scheme, a computerised
database that records hospital activity). Augmentation costs were
excluded, however, as induction is discouraged in women with
a previous caesarean delivery [31]. The average duration of labour
following a successful TOLAC, calculated from a case-control
study (conducted in a teaching hospital; results to be published),
was estimated at 7.5 hours in the base case. For the emergency
caesarean section group, a five-hour duration of labour was
assumed according to expert opinion. Variation in each of these
parameters was accounted for in the probabilistic sensitivity
analysis.
Consideration was also given to administrative costs (staff costs),
operational costs (overheads such as heating and lighting, building
Figure 1. Decision tree representing all possible consequences arising from the decision to undergo a TOLAC or ERCD.
doi:10.1371/journal.pone.0058577.g001
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maintenance), capital costs (land and building), and extended
length of stay costs. Administrative costs for midwives and
clinicians were obtained from consolidated salary scales [29].
Associated non-pay costs, including employer’s PRSI contribu-
tions, superannuation, and overheads, were also estimated [33,34].
Length of stay differed according to mode of delivery and
maternal morbidity status. Estimated length of stay during 2005–
2009 was derived from hospital discharge data (data derived from
HIPE). Median length of hospital stay was two days following
a successful vaginal delivery; three days following a ventouse
delivery and five days following a caesarean delivery. Length of
stay succeeding each maternal complication varied from five days
for uterine rupture and blood transfusion to six days following an
operative injury to 11 days for a hysterectomy. Representing the
top-down costing estimation, costs per bed-day were applied
where duration of stay exceeded two days since two days were
common to both groups. Bed-day costs were based on relevant
Diagnostic Related Groups, which represents groups of patients
who share similar clinical attributes and consume similar levels of
resources. The following DRG codes were used: DRG (O60B;
O01C; O02A; O01B).
As a measure of health gain, the cost-effectiveness analysis used
health-related quality of life, calculated as quality-adjusted life
years (QALY). A QALY can be described as a composite measure
of both length of life and health-related quality of life that can be
impacted by health care programmes and interventions [16]. It is
a generic measure of health which is widely used in clinical areas
to compare across various disease and illness conditions. A QALY
is typically calculated using a linear scale with two discrete points,
0.00 (death) and 1.00 (perfect health), where health-related quality
of life (also known as utility or weight) is assumed constant between
each interval. Taken from Chung et al [22], Quality of Well-Being
community preference weights were applied to represent the
disutility associated with each delivery pathway and complication
[30]. These weights described the scaled reduction in quality of life
across four dimensions of health: symptom complexes, mobility,
physical activity, and social activity. A modified weight and
duration of disutility was given to each dimension, according to
updated scales (Table 1). For example, the study assumed that an
unassisted vaginal delivery was associated with a disutility of 0.41,
lasting seven days, while ERCD was associated with a disutility of
0.58, lasting three weeks. QALYs were subsequently calculated by
multiplying the utility of each condition by the associated duration
of disutility, dependent on the study’s six week time frame. For
instance, following a successful vaginal delivery, a woman’s health
related quality of life yielded 0.93 QALYs over a six week time
frame or 0.99 QALYs over one year. A cost-effectiveness threshold
of J45,000 per QALY was applied in accordance with a historical
and notional Irish cost-effectiveness threshold [35].
An incremental cost-effectiveness ratio (ICER) was estimated
using the expected costs and effects of a TOLAC and an ERCD.
The estimated ICER represented the study’s base case cost-
effectiveness results or the deterministic model’s cost-effectiveness
results. Probabilistic sensitivity analysis was also performed to
account for parameter uncertainty. To do so, probability
distributions were assigned to the individual model parameters
(see Table S1). Costs and utilities assumed normal probability
distributions because the data informing the parameters were
unknown, whereas decision tree transition probabilities assumed
beta distributions because the input parameters were binomial.
(The range of the parameter estimates were typically determined
by the standard error of each input parameter; however, where the
standard error could not be identified, estimated figures were
assumed a priori, and a number of validation exercises were
performed to assess model stability). A Monte Carlo simulation
with 10,000 iterations was performed using Microsoft Excel
software (Microsoft, Seattle, WA). This simulation propagated the
uncertainty in the individual model parameters, reflected by the
assigned probability distributions, through the model to produce
a distribution of expected costs and effects associated with each
delivery mode. The results of the simulation were plotted on an
incremental cost-effectiveness plane where costs are plotted on the
north-south axis and effects are plotted on the east-west axis. An
incremental cost-effectiveness plane describes four quadrants. To
the north-east and south-west quadrant, an ICER is generated
where the costs and effects of the intervention are either higher
(north-east) or lower (south-west) than the control – a trade-off is
required. The north-west quadrant indicates higher costs but
lower effects such that the intervention is said to be dominated by
the control, while the south-east quadrant illustrates lower costs
and greater effects, where the intervention is said to dominate the
control [16]. The ICER was calculated using mean values of the
distributions of expected costs and effects.
Results
Costs and Maternal Outcomes
The cost of an unassisted vaginal delivery in Ireland was
estimated at J627.94 (Table 2). This estimation represents the
micro-costing of medical consumables, pharmaceuticals, and
medical staff. A ventouse delivery, which is associated with an
extended duration of stay, was estimated at J1,637.09. A modest
difference between the estimated cost of an emergency caesarean
section (J4,423.39) and an elective caesarean (J4,095.01) was
identified. However, both procedures differed considerably in
terms of staff costs as emergency caesarean section was associated
with increased staff costs due to extended duration of labour and
the increased necessity for the presence of specialised medical staff
at delivery, such as a neonatologist.
The decision analytic model evaluated maternal outcomes
among a hypothetical cohort of 10,000 women in each arm.
Following the decision to undergo a TOLAC, two-thirds of
women had a vaginal delivery (6,664) (Table 3). Of this group,
6,521 women (98%) had a complication-free vaginal delivery,
while 143 women (2%) experienced a maternal morbidity. Some
Table 1. Disutilities for each delivery pathway and
complication.
Health state QWB components
Disutility
per day
Duration
(days)
CPX MOB PAC SAC
Successful TOLAC 0.256 0.031 0.072 0.054 0.41 7
Emergency CS 0.424 0.031 0.072 0.054 0.58 21
ERCD 0.424 0.031 0.072 0.054 0.58 21
Uterine rupture 0.424 0.031 0.072 0.054 0.58 21
Hysterectomy 0.424 0.031 0.072 0.054 0.58 21
Operative injury 0.369 0.031 0.072 0.054 0.53 21
Blood transfusion 0.256 0.031 0.072 0.054 0.41 7
Endometritis 0.160 0.089 0.072 0.054 0.38 14
Source: QWB-SA scale (2008).
Abbreviations: CPX, symptom complexes; MOB, mobility; PAC, physical activity,
SAC, social activity; TOLAC, trial of labour after caesarean; CS, Caesarean section;
ERCD, Elective repeat Caesarean delivery.
doi:10.1371/journal.pone.0058577.t001
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867 women (13%) had a ventouse delivery. Uterine rupture
occurred in 24 instances across unassisted and assisted vaginal
deliveries, while endometritis arose in 87 cases. Following a failed
TOLAC, 465 women (14%) experienced an obstetric complica-
tion; uterine rupture occurred in 69 deliveries; operative injury
occurred in 91 deliveries; endometritis occurred in 277 deliveries.
In the ERCD group, uterine rupture was non-existent, while the
frequency of other morbidities rate was less than the TOLAC
group. Overall, maternal morbidities in the ERCD group (290
women) accounted for less than half the number of morbidities in
the TOLAC group (608 women). However, in one instance
a maternal death occurred in the ERCD group, but was essentially
absent following a TOLAC.
Deterministic Model
Despite a modestly higher rate of maternal morbidity following
a TOLAC, the results of the decision analytic model suggest that
a TOLAC is the cost-effective method of delivery for low risk
women. The main advantages of a TOLAC were realised in the
reduced length of stay in hospital and higher utility following
a vaginal delivery. In terms of health improvements, a TOLAC
generated 0.84 QALYs for a woman over the six week time frame,
while an ERCD was associated with 0.70 QALYs, accounting for
an incremental benefit of 0.14 QALYs (Table 4). This is based on
the total amount of QALYs available within a six week time frame,
or 0.1 of 0.12 QALYs available in a given year for a woman in the
TOLAC group. While the incremental effect is slight, the
difference in cost is considerable. The expected cost of a TOLAC
was J1,835.06 per woman, opposed to J4,039.87 for an ERCD.
Probabilistic Sensitivity Analysis
The aim of probabilistic sensitivity analysis was to examine the
existence and extent of uncertainty in the input parameters and,
hence, expected values. Results from the Monte Carlo simulations
(the point- and interval-estimate values used in the probabilistic
sensitivity analysis are detailed in Table S2), which are plotted in
the south-east quadrant of the incremental cost-effectiveness plane
(Figure 2), confirmed that a TOLAC was both less costly and more
effective than an ERCD. The expected cost of a TOLAC was
estimated at J1,833.56, yielding 0.84 QALYs per woman, while
Table 2. Estimated cost data for each delivery pathway and complication.
Successful TOLAC
unassisted
Successful TOLAC
ventouse Emergency CS ERCD
Delivery costs
Cost of medical consumables J104.44* J180.34* J173.06 J130.68
Staff costs J523.50 J573.75 J767.33 J481.33
Average length of stay (HIPE) 2 days 3 days 5 days 5 days
DRG cost per bed-day n/a J883 J1,161 J1,161
Total cost per woman (J) J627.94 J1,637.09 J4,423.39 J4,095.01
Complication costs Cost excluding mode of delivery
Uterine rupture J1,235.33
Hysterectomy J905.94
Operative injury J355.25
Blood transfusion J596.63
Endometritis J49.50
Abbreviations: TOLAC, trial of labour after caesarean; CS, Caesarean section; ERCD, Elective repeat Caesarean delivery; HIPE, Hospital in-patient enquiry scheme.
*This includes cost of epidural.
doi:10.1371/journal.pone.0058577.t002
Table 3. Distribution of maternal outcomes following a TOLAC and ERCD.
Successful TOLAC
(n=6,664)
Maternal outcome Unassisted (n=5,797) Ventouse (n =867)
Emergency CS
(n =3,336)
ERCD
(N=10,000)
Healthy 5,673 (98) 848 (98) 2,871 (86) 9,709 (97)
Total morbidity 124 (2) 19 (2) 465 (14) 290 (3)
Uterine rupture 21 (17) 3 (16) 69 (15) 0 (0)
Hysterectomy 5 (4) 1 (5) 7 (1) 11 (4)
Operative injury 4 (3) 1 (5) 91 (20) 56 (19)
Blood transfusion 19 (15) 3 (16) 20 (4) 27 (9)
Endometritis 76 (61) 11 (58) 277 (60) 196 (68)
Maternal mortality 0 (0) 0 (0) 0 (0) 1 (0)
doi:10.1371/journal.pone.0058577.t003
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an ERCD was estimated at J4,038.40 with an expected effect of
0.70 QALYs. Accordingly, the control group was said to be
dominated by the study’s intervention. This is illustrated in the
cost-effectiveness plane where individual trials do not cross the
vertical or horizontal axes. As such, the probability that a TOLAC
was cost-effective was 100 per cent.
Discussion
To our knowledge, this is the first detailed analysis comparing
the cost-effectiveness of a TOLAC to an ERCD in Europe (based
on the Euro currency). This study enhances existing costing
estimations as it is the first to rigorously employ a ‘‘bottom-up’’
costing technique in its evaluation of delivery and complication
costs. Estimated costs derive from an exhaustive costing process,
and may subsequently become the benchmark for costing obstetric
procedures and alternative deliveries in Ireland and Europe.
Further, we are unaware of any other study to date that has
incorporated the cost of an assisted delivery in its comparison with
ERCD.
Our hypothetical model found that a TOLAC was both less
costly and more effective than an ERCD, despite an increased risk
of maternal morbidity following a TOLAC. The main advantages
of a successful TOLAC were realised in the reduced length of stay
in hospital and higher utility following a vaginal delivery relative to
an ERCD.
Despite using a hypothetical model, our costing for a vaginal
delivery (J627.94) is in line with previous Irish reports (J631.64)
[36]. Moreover, our findings that a TOLAC is more cost-effective
than an ERCD were in accordance with research from the US
[21,22]. However, there were notable differences between the
studies. Chung et al [22] found that a TOLAC was the most cost-
effective method of delivery if the probability of successful
TOLAC was at least 74%. In contrast, this study found that
a TOLAC was cost-effective if the probability of success was 67%.
Varying the success rate between 64% and 69% did not alter the
cost-effectiveness results (see Tables S1–S2 for further information
on parameter ranges). Nonethless, these differences in the required
success threshold may be attributed in part to disparate costing
estimations. For instance, our study assumed the perspective of the
health system, while Chung et al [22] assumed a much broader
perspective, that of society. Grobman et al [21] also found that
a TOLAC was the cost-effective method of delivery relative to an
ERCD. Similar to our study, the results of the cost-effectiveness
analysis were robust to changes in key variables, such as cost and
probability variables.
Our study has several limitations. Firstly, our findings were
based on a hypothetical model and only focused on the major
short-term maternal complications arising from a TOLAC and an
ERCD. Other obstetric complications, such as thromboembolic
disease [37] and urinary incontinence [38], were not included due
to limited availability of published data. Moreover, inclusion of
potential adverse neonatal outcomes and long-term maternal
outcomes, such as increased risk of perinatal death, cerebral palsy,
sub-fertility [39,40] or placenta accreta [41], would have been
beyond the capabilities of the model and study timeline. These
issues should be explored in future research, where subsequent
iterations synthesize relevant evidence under a new and compre-
hensive decision model. Evidence synthesis plays a key role in
reducing uncertainty in decision making and should be the focus of
Table 4. Cost-effectiveness results of a TOLAC versus an
ERCD.
TOLAC ERCD ICER
Model Cost (J) QALYs Cost (J) QALYs (J/QALY)
Deterministic J1,830.73 0.84 J4,039.87 0.70 TOL dominates
Probabilistic J1,833.28 0.84 J4,041.54 0.70 TOL dominates
Abbreviations: TOLAC, trial of labour after caesarean; ERCD, elective repeat
Caesarean delivery; ICER, incremental cost-effectiveness ratio; QALY, quality-
adjusted life year.
doi:10.1371/journal.pone.0058577.t004
Figure 2. Results of 10,000 Monte Carlo simulations on the cost effectiveness plane for a TOLAC and ERCD.
doi:10.1371/journal.pone.0058577.g002
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future economic evaluations. Until the level of uncertainty in the
expected cost and clinical outcome is minimised, true cost-
effectiveness cannot be represented.
Secondly, maternal morbidity rates following a TOLAC versus
ERCD for our model were based on research from North
America, and thus may not be fully generalisable to an Irish
setting. For example, the prevalence of obesity in the US is
considerably higher than in Ireland [42], which may directly
impact the frequency of uterine rupture [43] and subsequently
overestimate its incidence in our study. Still, overestimating
uterine rupture incidence would only strengthen our conclusion
that a TOLAC is more cost-effective than an ERCD. In addition,
while we extracted our rates from a systematic review which
predominantly focused on morbidity rates in the USA, re-
assuringly, these rates are similar to those reported in other
developed countries, such as the UK and Australia [44–48].
Also, the model does not allow for comorbidities. While
probabilistic sensitivity analysis appropriately accounts for varia-
tions in each of the input parameters, it cannot account for
potential comorbidities within the cohort model. At present, the
incidence of comorbidities is not well documented, and research is
needed to determine the likelihood of multiple morbidities in
women with a previous caesarean section.
Lastly, with no utility index currently designed to measure
health gain following childbirth and obstetric complications, off-
the-shelf weights were applied to derive disutilities for vaginal and
caesarean deliveries. There is an inherent weakness in applying
community derived weights to represent health gain following
childbirth. A more rigorous utility index is ideal and should be
sought for future research.
Nevertheless, our results are timely and carry important
economic and public health implications. Given the substantial
increase in caesarean delivery across Europe over the past decade,
clinicians need to be well informed of both the short-term and
long-term benefits and risks of a TOLAC. Vaginal delivery should
be suggested as a birth option for low risk women where success of
a TOLAC is likely. Ideally, clinician-patient discourse would
address differences in length of hospital stay and postpartum
recovery time. While it is premature to advocate an institutional
policy of TOLAC, local maternity units and clinical managers
should be encouraged to evaluate their own rates of ERCD and
attempted TOLAC. Furthermore, to better understand barriers in
attempted TOLAC, mixed methods research focused on clinician
and patient preferences regarding mode of delivery should be
undertaken.
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